Malaria and HIV are two of the most important Infectious diseases worldwide that are overlapping and synergistic in sub-Saharan Africa. Despite the scale up of front line prevention efforts, the burden of malaria remains staggering among pregnant women and children;and malnutrition and growth retardation are major threats to child health. The purpose of the "Prevention of Malaria and HIV Disease in Tororo" (PROMOTE) program project (POI) is to evaluate promising interventions to reduce the burden of malaria and HIV and Improve maternal-child health through hypothesis based intervention studies. PROMOTE II will test the hypotheses that a) enhanced malaria chemoprevention in HIV infected and uninfected pregnant women will reduce placenta malaria;b) enhanced chemoprevention provided during both pregnancy and childhood will reduce malaria in children in the first 2 years of life and c) limiting in utero exposure to malaria antigens with enhanced malaria chemoprevention during pregnancy will reduce development of fetal immune tolerance to malaria antigens. The proposed clinical studies will evaluate chemoprevention with dihydroartemisinin-piperaquine (DP), a new artemisinin combination therapy (ACT), established as highly safe and effective for malaria treatment in pregnant women and children. PROMOTE II consists of 3 projects and 3 cores. There are 2 interlinked double blinded, randomized controlled trials in HIV-uninfected pregnant women (Project 1), and HIV-infected pregnant women (Project 2) and the children born to them with parallel structure that permits comparisons in malaria, immune responses and pharmacokinetics of DP between populations with differing HIV status and exposure. Project 3 is laboratory based, and is focused on testing central hypothesis of malaria immunity using well characterized specimens from the 2 clinical trials. Administrative, laboratory, and data cores provide infrastructure support to the projects, including the capacity to process and evaluate placental malaria using histopathology.
Malaria and HIV are among the most important diseases adversely affecting maternal child health in Africa. The PROMOTE studies seek to advance our knowledge of interventions that reduce the burden of malaria and HIV among pregnant women and their children living in rural Sub-Saharan Africa.
|Jagannathan, Prasanna; Nankya, Felistas; Stoyanov, Cristina et al. (2015) IFN? Responses to Pre-erythrocytic and Blood-stage Malaria Antigens Exhibit Differential Associations With Past Exposure and Subsequent Protection. J Infect Dis 211:1987-96|
|Kakuru, Abel; Achan, Jane; Muhindo, Mary K et al. (2014) Artemisinin-based combination therapies are efficacious and safe for treatment of uncomplicated malaria in HIV-infected Ugandan children. Clin Infect Dis 59:446-53|
|Bartelink, Imke H; Savic, Rada M; Mwesigwa, Julia et al. (2014) Pharmacokinetics of lopinavir/ritonavir and efavirenz in food insecure HIV-infected pregnant and breastfeeding women in Tororo, Uganda. J Clin Pharmacol 54:121-32|
|Koss, Catherine A; Natureeba, Paul; Plenty, Albert et al. (2014) Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy. J Acquir Immune Defic Syndr 67:128-35|
|Conrad, Melissa D; Bigira, Victor; Kapisi, James et al. (2014) Polymorphisms in K13 and falcipain-2 associated with artemisinin resistance are not prevalent in Plasmodium falciparum isolated from Ugandan children. PLoS One 9:e105690|
|Young, Sera L; Plenty, Albert H J; Luwedde, Flavia A et al. (2014) Household food insecurity, maternal nutritional status, and infant feeding practices among HIV-infected Ugandan women receiving combination antiretroviral therapy. Matern Child Health J 18:2044-53|
|Kamya, Moses R; Kapisi, James; Bigira, Victor et al. (2014) Efficacy and safety of three regimens for the prevention of malaria in young HIV-exposed Ugandan children: a randomized controlled trial. AIDS 28:2701-9|
|Bigira, Victor; Kapisi, James; Clark, Tamara D et al. (2014) Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. PLoS Med 11:e1001689|
|Ruel, Theodore D; Kakuru, Abel; Ikilezi, Gloria et al. (2014) Virologic and immunologic outcomes of HIV-infected Ugandan children randomized to lopinavir/ritonavir or nonnucleoside reverse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr 65:535-41|
|Ikilezi, Gloria; Achan, Jane; Kakuru, Abel et al. (2013) Prevalence of asymptomatic parasitemia and gametocytemia among HIV-infected Ugandan children randomized to receive different antiretroviral therapies. Am J Trop Med Hyg 88:744-6|
Showing the most recent 10 out of 15 publications